65,437 trials
Tuberous Sclerosis Complex · Seizures
Primary: Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE) — 117; 75; 80; 60…
Hemophilia B
Primary: Total Number of Participants Who Developed Inhibitors Against Factor IX (FIX) — 0; 1 Participants
Heart Failure
Primary: Telemetry — 0; 0; 0; 0 Participants
Recurrent Aphthous Stomatitis
Primary: Duration of RAS Lesions — 1.57 weeks
Cardiovascular Disease · Sarcopenia · Endothelial Dysfunction
Primary: Muscle Mitochondrial Function — 0.88; 0.90 mM ATP/s — p=0.15
Amyotrophic Lateral Sclerosis · Parkinson Disease · Dysphagia
Primary: Number of Participants With Residue of Concern (Observational) — 6; 6; 3; 6 Participants
General Surgery
Primary: Decreased Minute Ventilation (MV) — 20; 26 Participants
Disability Physical
Primary: Final Decisional Conflict Scale Score - Values Clarity Sub-scale — 13.1 units on a scale
Migraine · Migraine;Menstrual · Contraception
Primary: Serum Etonogestrel Concentrations — 142.0; 126.0; 119.0; 105.0 pg/mL
Spinal Cord Injuries · Deglutition Disorders
Primary: Number of Participants Displaying Unsafe Swallowing — 0; 0; 0; 0 Participants
Pain, Postoperative · Mammaplasty
Primary: Initial Visual Analog Scale (VAS) Pain Scores — 8.3; 7.4 score on a scale
Post Operative Pain
Primary: Pain Level — 5.67; 4.09 score on a scale
ALK-positive NSCLC
Primary: Overall Survival (OS): Based on Treatment Cohort Groups — 1.94; 2.30; 4.56; 2.94 Years
Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: PSA Progression-free Survival — 20.8; 16.5 Months — p=0.83
Superficial Bladder Cancer
Primary: Number of Patients With a Complete Response Rate Based on Patients With Carcinoma in Situ (CIS), With or Without Concomitant High-grade Ta or T1 Papillary Disease. — 55…